Intact Genomics

Intact Genomics is a privately held, revenue-generating biotech firm that operates as a hybrid platform, services, and diagnostics company. Its core innovation is the Fungal Artificial Chromosome (FAC) technology, enabling the capture and heterologous expression of large DNA fragments up to 300-500 kb for natural product discovery. The company commercializes a broad catalog of research reagents while offering custom R&D services through its igTherapeutics® division, targeting novel drug discovery from fungal and environmental microbiomes. With ISO-certified manufacturing and a focus on cutting-edge isothermal amplification and cloning tools, Intact Genomics supports academic, agricultural, and pharmaceutical research sectors.

Fungal Artificial Chromosome (FAC) and large DNA fragment capture technology for heterologous expression of biosynthetic gene clusters (up to 300-500 kb) in fungal hosts, enabling natural product discovery.

In reagents, Intact Genomics competes with New England Biolabs, Thermo Fisher, and Takara Bio in niche cloning and amplification products. In the discovery services space, it competes with synthetic biology firms like Ginkgo Bioworks (which uses engineered yeast/bacteria) and other specialized natural product discovery companies, differentiating itself with its fungal-specific large-DNA capture and expression expertise.